8-K: DaVita Inc. Reports Mixed Q1 2024 Results Amidst Cyberattack Impact

DaVita Inc. announced its first quarter 2024 financial results, showing revenue growth but facing challenges from a cyberattack and increased costs.

Summary

• DaVita Inc. reported consolidated revenues of $3.071 billion for the first quarter of 2024.
• Operating income was $484 million, with an adjusted operating income of $463 million.
• Diluted earnings per share were $2.65, and adjusted diluted earnings per share were $2.38.
• The company experienced a negative operating cash flow of $(135) million and a negative free cash flow of $(327) million.
• DaVita repurchased 2.1 million shares of its common stock at an average price of $112.76 per share.
• U.S. dialysis treatments totaled 7,151,512, averaging 92,159 per day, a slight decrease of 0.4% compared to the previous quarter.
• Normalized non-acquired treatment growth was 0.4% compared to the first quarter of 2023.
• The company incurred $14.6 million in charges for U.S. dialysis center closures.
• DaVita received $472 million in interest-free funding from UnitedHealth Group to mitigate the impact of the Change Healthcare cyberattack.
• As of March 31, 2024, DaVita provided dialysis services to approximately 258,600 patients at 3,092 outpatient centers.
• The company has approximately 68,600 patients in risk-based integrated care arrangements, representing $5.3 billion in annualized medical spend.

Sentiment

Score: 4

Explanation: The document presents mixed results with some positive aspects like revenue growth and share repurchases, but significant negatives such as negative cash flow and the impact of the cyberattack. The forward-looking statements are cautious, and the overall tone suggests a challenging quarter.

Positives

• DaVita's consolidated revenues increased to $3.071 billion.
• The company achieved a net income of $240 million, a significant increase from $116 million in the same quarter last year.
• DaVita repurchased 2.1 million shares of its common stock, indicating confidence in the company's value.
• The company secured $472 million in interest-free funding to mitigate the impact of the Change Healthcare cyberattack.
• DaVita's integrated kidney care business continues to grow, with $5.3 billion in annualized medical spend.

Negatives

• Operating cash flow was negative at $(135) million, and free cash flow was also negative at $(327) million.
• U.S. dialysis treatments saw a slight decrease of 0.4% per day compared to the previous quarter.
• The company incurred $14.6 million in charges related to U.S. dialysis center closures.
• The Change Healthcare cyberattack caused delays in claims processing and negatively impacted operating cash flows.
• The company experienced an increase in outstanding borrowings under its revolving credit facility.

Risks

• The Change Healthcare cyberattack caused significant disruptions in claims processing and negatively impacted cash flow.
• The company faces ongoing challenges from macroeconomic conditions, including inflation and labor market pressures.
• There is a risk of reduced reimbursement rates from government and commercial payors.
• DaVita is exposed to potential legal and compliance risks, including those related to healthcare regulations.
• The company faces increased competition from other dialysis providers and potential new entrants in the market.
• There is uncertainty regarding the impact of new technologies and treatments on the dialysis industry.
• The company's forward-looking statements are subject to significant risks and uncertainties, including those related to the COVID-19 pandemic.

Future Outlook

DaVita provided 2024 guidance for adjusted operating income between $1.875 billion and $1.975 billion, adjusted diluted net income per share between $9.00 and $9.80, and free cash flow between $900 million and $1.150 billion. The company noted that these forward-looking measures are subject to significant risks and uncertainties.

Management Comments

• Javier Rodriguez, CEO of DaVita Inc., stated that the company continued building on the momentum generated through 2023, demonstrating operational discipline while continuing to find opportunities to invest, innovate and most importantly deliver clinical excellence.

Industry Context

The healthcare industry is facing increasing challenges from cyberattacks, as evidenced by the Change Healthcare outage. DaVita's results reflect the impact of these challenges, as well as the ongoing pressures on reimbursement rates and the need to adapt to new care models. The company's focus on integrated kidney care aligns with the industry trend towards value-based care.

Comparison to Industry Standards

• DaVita's revenue per treatment of $384.54 is a key metric to compare against other dialysis providers such as Fresenius Medical Care, which also reports similar metrics.
• The negative operating and free cash flow for the quarter is concerning and would be compared to the cash flow performance of competitors to assess DaVita's relative financial health.
• The company's leverage ratio of 3.29x is within the permitted range of 5.00x under its credit agreement, but it is important to compare this to the leverage ratios of other healthcare companies with similar debt profiles.
• The number of dialysis treatments and patient volumes are key indicators of market share and operational efficiency, and these would be compared to the performance of other major dialysis providers.
• The $14.6 million in center closure costs is a significant expense and would be compared to similar costs incurred by competitors to assess DaVita's strategic decisions regarding clinic capacity.

Stakeholder Impact

• Shareholders may be concerned about the negative cash flow and the impact of the cyberattack on the company's financial performance.
• Employees may be affected by the ongoing cost savings initiatives and potential changes in operations.
• Patients may experience disruptions in service due to the cyberattack and center closures.
• Suppliers may be impacted by changes in the company's procurement strategies.
• Creditors may be concerned about the company's increased borrowings and negative cash flow.

Next Steps

• DaVita will hold a conference call on May 2, 2024, to discuss the first quarter results.
• The company will continue to monitor and address the impact of the Change Healthcare cyberattack.
• DaVita will continue to implement its cost savings initiatives and strategic plans.

Key Dates

Keywords

dialysis, healthcare, financial results, cyberattack, integrated kidney care, revenue, operating income, earnings per share, cash flow, share repurchase, treatment volume, center closures